Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B
Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx for $28 each was expected have a value of $1.9 billion net of estimated cash required.Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Johnson & Johnson will acquire cancer-treatment developer AmbrxBiopharma in a $2 billion cash deal.The pharmaceutical giant said Monday that the…